MEI Pharma Adds Former VC David Urso as Senior Vice President of Corporate Development and General Counsel
PR Newswire - Tue Apr 08, 7:30AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today the appointment of David Urso as Senior Vice President of Corporate Development and General Counsel. Mr. Urso joins MEI Pharma with more than two decades of experience in the life science industry, most recently as Chief Operating Officer and General Counsel at Tioga Pharmaceuticals, a company he co-founded in 2005 as a Principal at Forward Ventures.
MEI Pharma Identifies Potential Biomarker For Pracinostat In Bladder Cancer
PR Newswire - Mon Apr 07, 7:30AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced the presentation of new pre-clinical data showing the ability of its lead drug candidate Pracinostat to inhibit bladder cancer cell growth and induce activated transcription factor 3 (ATF-3) expression, a potential marker of tumor response. The data were presented yesterday at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.
MEI Pharma To Present At Needham Healthcare Conference
PR Newswire - Tue Apr 01, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Needham Healthcare Conference on Tuesday, April 8, 2014 at 3:00 p.m. Eastern time from the Westin Grand Central Hotel in New York City. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEI Pharma, Inc. (MEIP) in Focus: Stock up 12.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 7:44AM CDT
MEI Pharma, Inc. was a big mover last session, as the company saw its shares rise over 12% on the day.
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 27, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
3 Stocks Spiking on Big Volume
at The Street - Thu Mar 27, 8:11AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
MEI Pharma (MEIP) Crumbles: Stock Falls by 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 7:53AM CDT
MEI Pharma, Inc. (MEIP) saw a big move last session, reversing the recent trend for MEIP as the stock is now up around 17.2% in the past one-month time frame.
4 Stocks Under $10 Triggering Breakouts
at The Street - Fri Mar 07, 5:00AM CST
These under-$10 stocks are within range of triggering breakout trades.
MEI Pharma (MEIP) is Overbought, What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:21AM CST
MEI Pharma (MEIP) is Overbought, What’s Next?
MEI Pharma Receives Orphan Status For Lead Drug Candidate Pracinostat For Treatment Of Acute Myeloid Leukemia
PR Newswire - Fri Feb 28, 7:33AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML).
MEI Pharma To Present At Cowen Health Care And ROTH Conferences
PR Newswire - Tue Feb 25, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
Evidera And Symphony Technology Group Announce Appointment Of Simon Kennedy To Senior Leadership Roles
PR Newswire - Tue Feb 11, 8:00AM CST
Evidera, a leading provider of evidence-based solutions for the healthcare industry, and Symphony Technology Group (STG) (STG), a strategic private equity firm, today announced that Simon Kennedy has joined Evidera as executive chairman of the board, effective January 1. In this position, he plays a leadership role in defining Evidera's acquisition, new product development and overall growth strategies, working closely with Evidera's management team. Kennedy has also joined STG as healthcare operations partner, and another portfolio company, Symphony Health Solutions, as a member of the board of directors.
5 Stocks Ready to Break Out
at The Street - Fri Jan 31, 12:59PM CST
These stocks look ready to break out and trade higher from current levels.
Atlantic Power Corporation Announces Launch by Atlantic Power Limited Partnership of Syndication of New Senior Secured Credit Facilities
PR Newswire - Thu Jan 30, 7:30AM CST
Atlantic Power Corporation (TSX: ATP; NYSE: AT) (the "Company"
4 Biotech Stocks Under $10 Making Big Moves
at The Street - Wed Jan 29, 6:00AM CST
Keep these under-$10 biotech stocks on your radar.
'Why De-Registered Parties Joined PDP'
by Misbahu Bashir - All Africa Global Media - Tue Jan 21, 3:32AM CST
Chairman of the defunct United Nigeria Peoples Party (UNPP) Alhaji Inuwa Ahmed, yesterday at a media briefing in Kaduna explained why 23 de-registered political parties joined the ruling People's Democratic Party (PDP).
Pipeline Progress at MEI Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 4:30PM CST
MEI Pharma announced that it has dosed the first patient in its phase II study on its pipeline candidate pracinostat for the treatment of patients with MDS
MEI Pharma Inc begins Phase II clinical trial of Pracinostat in refractory myelodysplastic syndrome
M2 - Wed Jan 15, 11:03AM CST
Oncology company MEI Pharma Inc (NasdaqCM:MEIP) reported on Tuesday the dosing of the first patient in a Phase II clinical trial of Pracinostat in patients with myelodysplastic syndrome (MDS).
MEI Pharma Initiates Phase II Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome
PR Newswire - Tue Jan 14, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase II clinical trial of Pracinostat, the Company's investigational oral histone deacetylase (HDAC) inhibitor, in patients with myelodysplastic syndrome (MDS) who either failed to respond or maintain a response to a hypomethylating agent (HMA) alone.